Trial Profile
A Phase 2, Open-Label Randomized Study to Evaluate the Efficacy and Safety of the Combination Product, Emtricitabine/Tenofovir Disoproxil Fumarate in the Presence or Absence of Hepatitis B Immunoglobulin (HBIg) in Preventing Recurrence of Chronic Hepatitis B (CHB) Post-Orthotopic Liver Transplant (OLT)
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Emtricitabine/tenofovir disoproxil fumarate (Primary) ; Hepatitis B immune globulin
- Indications Hepatitis B
- Focus Therapeutic Use
- Sponsors Gilead Sciences
- 03 May 2012 Actual end date (May 2011) added as reported by ClinicalTrials.gov.(NCT00507689)
- 03 May 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.(NCT00507689)
- 04 May 2011 Interim results presented at the American Transplant Congress -- 11th Joint Congress of the American Society of Transplant Surgeons and the American Society of Transplantation.